#Peptides

What the New Federal Peptide Framework Means for Pharmacists and Patients

What the New Federal Peptide Framework Means for Pharmacists and Patients

The U.S. Department of Health and Human Services has issued an interim framework that lets state-licensed pharmacies compound several specific peptides while formal rulemaking continues. The FDA's Pharmacy Compounding Advisory Committee is also scheduled to review five more peptides by the end of February. Industry leaders say the policy is shifting how pharmacists and prescribers think about these therapies, but they stress that enforcement discretion is not FDA approval and that clinical safety data remains limited. For pharmacists, the message is clear: rely on professional judgment, stay current, and evaluate each patient carefully.

Draft HHS Peptide Policy Puts Pharmacists Between Access and Caution

Draft HHS Peptide Policy Puts Pharmacists Between Access and Caution

As the comment period closes on a Department of Health and Human Services draft policy, pharmacy leaders are being urged to wait for the final version from the FDA before changing operations. The draft would let state-licensed 503A pharmacies compound six unapproved peptides, including BPC-157 and TB-500, without federal enforcement action. Supporters say the shift could bring patients into regulated channels and away from gray-market sellers. FDA reviewers, the American Medical Association, and the American Pharmacists Association have raised safety and evidence concerns. Pharmacists weighing entry into peptide compounding should verify ingredient sourcing, documentation, adverse event reporting, and state rules while the policy remains in draft form.

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some under 12, according to a Guardian investigation of NHS prescribing data. In the 2025-26 financial year, 419 prescriptions were issued to under-18s, 10 of them to children under 12. Experts say the figures likely understate the true total, and they stress that children who start these drugs need specialist supervision and long-term monitoring. The findings come as childhood obesity rates continue to rise and as new global guidance advises against giving obesity medications to children under 10.